Prediction of 2 years-survival in patients with stage I and II non-small cell lung cancer utilizing 18F-FDG PET/CT SUV quantification

Radiology and Oncology

Volumn 47, Issue 3, 2013, Pages 219-223

  Cistaro, Angelina ^a   Quartuccio, Natale ^b   Mojtahedi, Alireza ^c   Fania, Piercarlo ^a   Filosso, Pier Luigi ^d   Campenni, Alfredo ^b   Ficola, Umberto ^e   Baldari, Sergio ^b  

^a Positron Emission Tomography Centre IRMET SpA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MOLINETTE HOSPITAL   (Italy)

^e LA MADDALENA CANCER CENTER   (Italy)

Author keywords

2 deoxy 2 18F fluoro D glucose positron emission tomography; Disease free survival; Maximum standardized uptake value; Non small cell lung cancer; Overall survival

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MIDDLE AGED; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PET-CT SCANNER; PRIMARY TUMOR; QUANTITATIVE ANALYSIS; RADIOLOGICAL PARAMETERS; SURVIVAL PREDICTION;

EID: 84886566321     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2013-0023     Document Type: Article

References (28)

1. WHO Department of Gender, Women and Health. Gender in lung cancer and smoking research. Geneva: World Health Organization; January 2004. p. 8.
2. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348: 2500-7.
3. Baum RP, Hellwig D, Mezzetti M. Position of nuclear medicine modalities in the diagnostic workup of cancer patients: lung cancer. Q J Nucl Med Mol Imaging 2004; 48: 119-42.
4. Hellwig D, Baum RP, Kirsch C. FDG PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 2009; 48: 59-69.
5. Vansteenkiste J, Fisher BM, Dooms C, Mortensen J. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 2004; 5: 531-40.
6. Chen HH, Chiu NT, Su WC, Guo HR, Lee BF. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012; 264: 559-66.
7. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J, et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008; 3: 130-4.
8. 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2011; 38: 1628-35.
9. Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, et al. (18) F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib. J Nucl Med 2011; 52: 1684-9.
10. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in earlystage non-small cell lung cancer. Ann Thorac Surg 1995; 60: 466-72.
11. Gümüştaş S, Inan N, Akansel G, Ciftçi E, Demirci A, Ozkara SK. Differentiation of malignant and benign lung lesions with diffusion-weighted MR imaging. Radiol Oncol 2012; 46: 106-13.
12. Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Physician 2007; 75: 56-63.
13. Andrade RS, Odell DD, D'Cunha J, Maddaus MA. Endobronchial ultrasonography (EBUS) - Its role in staging of non-small cell lung cancer and who should do it? J Thorac Cardiovasc Surg 2012; 144: S9-S13.
14. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th edition. New York: Springer; 2010. p. 299-324.
15. Eisenhauera EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
16. Beadsmoore CJ, Screton NJ. Classification, staging and prognosis of lung cancer. Eur J Radiol 2003; 45: 8-17.
17. Weber WA, Ziegler SI, Thodtmann R, Hanauske AR, Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999; 40: 1771-7.
18. Huang SC. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 2000; 27: 643-6.
19. Adams MC, Turkington TG, Wilson JM, Wong TZ. A systematic review of the factors affecting accuracy of SUV Measurements. AJR Am J Roentgenol 2010; 195: 1043.
20. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010; 37: 181-200.
21. Cerfolio RJ, Bryant AS, Ohja B, Bartolucci AA. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival. J Thorac Cardiovasc Surg 2005; 130: 151-9.
22. Van Baardwijk A, Dooms C, Van Suylen RJ, Verbeken E, Hochstenbag M, Dehing-Oberije C, et al. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer. Eur J Cancer 2007; 43: 1392-8.
23. 18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005; 23: 1136-43.
24. Jeong HJ, Min JJ, Park JM, Kim BT, Jeong JM, Lee DS, et al. Determination of the prognostic value of [(18)F] fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002; 23: 865-70.
25. Downey RJ, Akhurst T, Gonen M, Vincent A, Bains MS, Larson S, et al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22: 3255-60.
26. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE, et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: New contrary data on prognostic role. Clin Cancer Res 2007; 13: 3255-63.
27. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17: 3201-6.
28. Hanin FX, Lonneux M, Cornet J, Noirhomme P, Coulon C, Distexhe J, et al. Prognostic value of FDG uptake in early stage non-small cell lung cancer. Eur J Cardiothorac Surg 2008; 33: 819-23.